ABL1 and acute lymphoblastic leukemia: In pediatrics, the newly opened COG AALL2131/EsPhALL 2022 study (NCT06124157) is exploring an immuno-chemotherapeutic approach with the early introduction of blinatumomab to replace conventional chemotherapy and the combination of fusion-specific TKI therapy for patients with newly diagnosed Ph+ or ABL-class ALL.